NASDAQ:PRAH - PRA Health Sciences Stock Price, News, & Analysis

PRA Health Sciences trades on the NASDAQ under the ticker symbol "PRAH."

PRA Health Sciences Inc (NASDAQ:PRAH) announced its quarterly earnings data on Wednesday, August, 1st. The medical research company reported $1.00 earnings per share for the quarter, beating analysts' consensus estimates of $0.88 by $0.12. The medical research company had revenue of $722.84 million for the quarter, compared to analyst estimates of $706.57 million. PRA Health Sciences had a net margin of 4.25% and a return on equity of 24.52%. The business's quarterly revenue was up 35.4% compared to the same quarter last year. During the same period in the previous year, the company earned $0.79 earnings per share. View PRA Health Sciences' Earnings History.

PRA Health Sciences is scheduled to release their next quarterly earnings announcement on Wednesday, October, 24th 2018. View Earnings Estimates for PRA Health Sciences.

PRA Health Sciences updated its FY18 earnings guidance on Wednesday, August, 1st. The company provided earnings per share guidance of $4.13-4.23 for the period, compared to the Thomson Reuters consensus estimate of $4.12. The company issued revenue guidance of $2.87-2.92 billion, compared to the consensus revenue estimate of $2.92 billion.

8 equities research analysts have issued 12 month price objectives for PRA Health Sciences' stock. Their forecasts range from $94.00 to $115.00. On average, they expect PRA Health Sciences' share price to reach $107.25 in the next twelve months. This suggests a possible upside of 5.5% from the stock's current price. View Analyst Price Targets for PRA Health Sciences.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PRA Health Sciences in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for PRA Health Sciences.

Some companies that are related to PRA Health Sciences include Iqvia (IQV), Incyte (INCY), Icon (ICLR), EXACT Sciences (EXAS), Exelixis (EXEL), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), BTG (BTGGF), Medpace (MEDP), Intrexon (XON), National Research (NRCIB), National Research (NRCIA), Sorrento Therapeutics (SRNE), Eloxx Pharmaceuticals (ELOX) and Pieris Pharmaceuticals (PIRS).

(PRAH) raised $306 million in an initial public offering on Thursday, November 13th 2014. The company issued 17,000,000 shares at $18.00 per share. Jefferies, Citigroup, KKR, UBS Investment Bank, Credit Suisse and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

News coverage about PRAH stock has trended somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. PRA Health Sciences earned a media and rumor sentiment score of 0.12 on Accern's scale. They also assigned headlines about the medical research company an impact score of 44.70 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term. View Recent Headlines for PRA Health Sciences.

PRA Health Sciences' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.43%), FMR LLC (3.57%), Bank of New York Mellon Corp (3.43%), Eagle Asset Management Inc. (1.61%), Voya Investment Management LLC (1.59%) and Acadian Asset Management LLC (1.58%). Company insiders that own PRA Health Sciences stock include Colin Shannon, David W Dockhorn, Linda Baddour, Matthew P Young and Pra Investors LP Kkr. View Institutional Ownership Trends for PRA Health Sciences.

PRAH stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Russell Investments Group Ltd., Eagle Asset Management Inc., Hood River Capital Management LLC, Voya Investment Management LLC, Carillon Tower Advisers Inc., Castleark Management LLC and Schwab Charles Investment Management Inc.. Company insiders that have sold PRA Health Sciences company stock in the last year include David W Dockhorn, Linda Baddour, Matthew P Young and Pra Investors LP Kkr. View Insider Buying and Selling for PRA Health Sciences.

PRAH stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., FMR LLC, Bank of New York Mellon Corp, Jennison Associates LLC, Bellevue Group AG, Paloma Partners Management Co, Tesco Pension Investment Ltd and Jane Street Group LLC. View Insider Buying and Selling for PRA Health Sciences.

Shares of PRAH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PRAH stock can currently be purchased for approximately $101.68.

PRA Health Sciences has a market capitalization of $6.53 billion and generates $2.26 billion in revenue each year. The medical research company earns $86.92 million in net income (profit) each year or $3.20 on an earnings per share basis. PRA Health Sciences employs 15,800 workers across the globe.

PRA Health Sciences' mailing address is 4130 PARKLAKE AVENUE SUITE 400, RALEIGH NC, 27612. The medical research company can be reached via phone at 919-786-8200 or via email at [email protected]